Abstract

Kimberly-Clark will report second-quarter 2026 results on August 04, 2026 Pre-Market; this preview summarizes consensus forecasts for revenue, margins, net income, and adjusted EPS alongside segment dynamics and prevailing analyst views.

Market Forecast

Consensus for the current quarter points to revenue of 4.22 billion US dollars, an EBIT estimate of 705.04 million US dollars, and adjusted EPS of 2.01, implying a year-over-year EPS increase of 20.30% and a revenue decrease of 9.78%. EBIT is projected to decline by 3.18% year over year. The company’s last update implies mixed margin trends for this quarter, with EPS uplift driven by pricing and mix offsetting volume and currency pressures; no specific gross margin or net margin forecast was disclosed in market figures collected. Management focus centers on core tissue and personal care categories, with stable demand in North America and a steady recovery in select international markets; the outlook highlights disciplined pricing and productivity. Among segments, Baby and Child Care remains the most promising, with last quarter revenue of 1.70 billion US dollars and solid contribution to growth based on prior-year comparisons.

Last Quarter Review

In the previous quarter, Kimberly-Clark reported revenue of 4.16 billion US dollars, a gross profit margin of 37.86%, GAAP net profit attributable to shareholders of 665.00 million US dollars with a net profit margin of 15.97%, and adjusted EPS of 1.97, with year-over-year adjusted EPS growth of 2.07%. A key highlight was margin resilience, as gross margin held near 38% supported by pricing discipline and cost savings despite softer top-line trends. By business mix, Baby and Child Care generated 1.70 billion US dollars, while Family Care delivered 1.04 billion US dollars, Professional posted 0.46 billion US dollars, Adult Care reached 0.48 billion US dollars, and Feminine Care contributed 0.45 billion US dollars; segment-level year-over-year data was not disclosed in the collected feed.

Current Quarter Outlook

Core Tissue and Personal Care

Kimberly-Clark’s core tissue and personal care franchise drives the bulk of revenue and margin outcomes this quarter. With forecast revenue at 4.22 billion US dollars and EBIT at 705.04 million US dollars, the earnings mix suggests continued pricing carryover and productivity gains under the company’s ongoing efficiency initiatives. The expected year-over-year EPS increase of 20.30% is consistent with cost leverage and a more favorable input-cost environment compared to prior periods, though revenue is forecast to contract by 9.78% on tougher comparisons and currency impacts captured in market estimates. Net margin should track near recent levels given the projected EBIT decline of 3.18%, but EPS growth implies lower below-the-line items and leaner cost structure. Execution around promotional cadence and shelf positioning in North America will be crucial to defending share and preserving price architecture, particularly in Family Care, where private-label competition has been most active.

Baby and Child Care as Growth Engine

Baby and Child Care, at 1.70 billion US dollars last quarter, remains a pivotal driver for top-line quality and premiumization. The portfolio’s exposure to premium diapers and pants supports category price/mix, and global brand equity should underpin resilience across channels. Assuming stable category demand in developed markets and steady normalization in select emerging markets, the segment is positioned to contribute a disproportionate share of EBIT through higher-margin SKUs. Key watch items this quarter include promotional intensity in North America mass retail, elasticity response in premium tiers, and the cadence of innovation rollouts that support trade-up. Given volume sensitivity and foreign exchange translation, sustaining mix improvements is vital for translating pricing into EPS accretion even if headline revenue is forecast to decline year over year.

Stock Price Sensitivities This Quarter

Three factors are likely to have the strongest influence on the share reaction surrounding the print. The first is revenue trajectory versus the 4.22 billion US dollars consensus; an in-line revenue result coupled with better-than-expected profitability could still drive a positive response, while a top-line miss would amplify concerns around elasticity and competitive intensity. The second is gross margin progression versus the prior quarter’s 37.86% level; continued improvement supported by lower pulp and input costs would validate the EPS forecast uplift, whereas any reversal due to pricing or mix pressure could challenge the sustainability of a 20.30% EPS growth profile. Third, management commentary on pricing, volume, and productivity targets into the back half will frame the path for EBIT, especially with the current estimate implying a 3.18% year-over-year decline; clarity on cost savings and brand investment timing will be pivotal for valuation narratives.

Analyst Opinions

The majority of compiled commentary over the past six months trends neutral-to-cautious, leaning toward limited upside into the print given the revenue decline implied by consensus and a modestly lower EBIT trajectory. Analysts flag that while EPS is supported by cost controls and productivity, the balance between pricing and volume remains delicate in competitive categories such as Family Care and Feminine Care. Several institutions emphasize that sustaining high-30s gross margin hinges on disciplined promotion and stable input costs; any deviation could compress the EPS bridge despite lower below-the-line pressures. On balance, the prevailing view expects results roughly in line with the 4.22 billion US dollars revenue and 2.01 adjusted EPS figures, with management outlook and pricing commentary serving as the primary catalysts for share movement.